StockWatch
·
Biotechnology: Pharmaceutical Preparations
Quarterly ResultApr 29, 2026, 07:12 AM

AMRN Q1 Net Loss $(10.5)M; Revenue $45.1M; Restructuring

AI Summary

Amarin Corp PLC reported a net loss of $(10.5) million for Q1 2026, an improvement from $(15.7) million in Q1 2025, with total revenue increasing to $45.1 million from $42.0 million. The company recognized $3.3 million in restructuring expenses during the quarter as part of its Global Restructuring Plan, which has incurred cumulative charges of $39.6 million. Despite revenue growth, gross margin declined, and cash and cash equivalents decreased.

Key Highlights

  • Q1 2026 Net Loss $(10.5)M, improved from $(15.7)M YoY.
  • Q1 2026 Total Revenue $45.1M, up from $42.0M YoY.
  • Q1 2026 Product Revenue $43.3M, up from $41.0M YoY.
  • Q1 2026 Gross Margin $17.8M, down from $25.1M YoY.
  • Q1 2026 Operating Expenses $29.1M, down from $41.9M YoY.
  • Q1 2026 Restructuring Expense $3.3M; cumulative $39.6M.
  • Cash & Cash Equivalents $131.1M as of March 31, 2026.
  • No debt outstanding as of March 31, 2026.